Floatz logo

azd6738

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Samsung Medical CenterPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

291 Active assets in the Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
Carboplatin
University of Maryland, Baltimore
Phase 4BB

View all 50 →

Same molecule, other indications

azd6738 is also rated in:

adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian serous adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →